Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07177066
PHASE1

A Study of EDG-15400 in Healthy Adults

Sponsor: Edgewise Therapeutics, Inc.

View on ClinicalTrials.gov

Summary

The purposes of this Phase 1 study of EDG-15400 are to: 1. Learn about the safety of EDG-15400 after single and multiple doses in healthy adults 2. Learn about how EDG-15400 is tolerated after single and multiples doses in healthy adults 3. Evaluate the amount of EDG-15400 in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-15400 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-15400 in the blood is similar for the suspension and tablet forms of EDG-15400 in healthy adults Participants will receive a single or multiple doses of EDG-15400 or a placebo by mouth.

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 59 Years

Study Type

INTERVENTIONAL

Enrollment

108

Start Date

2025-08-20

Completion Date

2026-05

Last Updated

2025-09-16

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

EDG-15400

EDG-15400 is administered orally

DRUG

Placebo

Placebo is administered orally

Locations (1)

Celerion, Inc.

Tempe, Arizona, United States